Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Revolution Medicines has posted the financial and operational updates for the first quarter of 2024, emphasizing significant advancements in its novel RAS(ON) inhibitor pipeline.</li><li>The company continues to prioritize advancing RMC-6236 into pivotal monotherapy trials in major cancers driven by oncogenic RAS variants, with a strong focus on expanding the clinical applications of RMC-6236 beyond G12X mutations into different RAS genotypes and tumor types.</li><li>In the past quarter, Revolution Medicines has provided encouraging preclinical and clinical data, particularly highlighting the potential of RMC-6236 in treating various cancers, including pancreatic ductal adenocarcinoma and non-small cell lung cancer.</li></ul>

Revolution Medicines has posted the financial and operational updates for the first quarter of 2024, emphasizing significant advancements in its novel RAS(ON) inhibitor pipeline.The company continues to prioritize advancing RMC-6236 into pivotal monotherapy trials in major cancers driven by oncogenic RAS variants, with a strong focus on expanding the clinical applications of RMC-6236 beyond G12X mutations into different RAS genotypes and tumor types.In the past quarter, Revolution Medicines has provided encouraging preclinical and clinical data, particularly highlighting the potential of RMC-6236 in treating various cancers, including pancreatic ductal adenocarcinoma and non-small cell lung cancer.

Revolution Medicines Inc.: Focus on Novel Combo-Therapeutic Approaches and Broader Genetic Mutations & Other Major Developments - Financial Forecasts

<ul><li>Revolution Medicines reported a decent set of earnings call for the fourth quarter and full year of 2023.</li><li>Throughout the year, Revolution made significant strides, such as revealing the preliminary clinical profiles of two targeted RAS(ON) inhibitors, RMC-6236 and RMC-6291, from Phase I/IIb trials.</li><li>According to data from the Triple Meeting and ESMO Congress, these investigational drugs show promise and support continued development.</li></ul>

Revolution Medicines reported a decent set of earnings call for the fourth quarter and full year of 2023.Throughout the year, Revolution made significant strides, such as revealing the preliminary clinical profiles of two targeted RAS(ON) inhibitors, RMC-6236 and RMC-6291, from Phase I/IIb trials.According to data from the Triple Meeting and ESMO Congress, these investigational drugs show promise and support continued development.

Revolution Medicines Inc.: Initiation Of Coverage - Progression Of Clinical Development Programs & Other Major Drivers

Smartkarma Research Team, Smartkarma

Smartkarma Research

Smartkarma Research Team

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<div>
<p><strong>[UPDATE: This webinar has been postponed until further notice]</strong></p>
<ul style="list-style-type: disc;">
<li>In the next installment of our Webinar series, we go live with Smartkarma Insight Provider <a href="https://www.smartkarma.com/profiles/andrei-zakharov" target="_blank" data-smartkarma-citation="accounts:12122" rel="noopener">Andrei Zakharov</a> </li>
<li>He will be discussing some U.S. SaaS stocks, crypto mining companies as part of his High Conviction Trade Ideas in the US.</li>
<li>He will also be sharing his insights into his high-conviction trade idea in biotech - oncology-focused company, Revolution Medicines. </li>
</ul>
</div>
<div>
<h3>The webinar will be hosted on Wednesday, 14 August 2023, 17:00 SGT/HKT.</h3>
</div>
<div>
<div>
<div>
<div class="content-highlight">
<h2><a href="https://share.hsforms.com/1H9pFZOB-RF2J00kbvMmxcw2c5gj?zoom_webinar_id=86111920818" target="_blank" rel="noopener">Register for the Webinar here</a></h2>
</div>
</div>
</div>
</div>
<div>
<p><a href="https://www.smartkarma.com/profiles/andrei-zakharov" target="_blank" data-smartkarma-citation="accounts:12122" rel="noopener">Andrei Zakharov</a> is the founder of independent equity research firm Algosun Global Limited, with broad professional experience at leading multinational banks Citibank and Morgan Stanley. Andrei has a respectable background in wealth advisory services for UHNW individuals, alternative energy buy-side research, in-depth analysis of pre-IPO technology unicorns, and portfolio management.</p>
</div>


[UPDATE: This webinar has been postponed until further notice]

In the next installment of our Webinar series, we go live with Smartkarma Insight Provider Andrei Zakharov 
He will be discussing some U.S. SaaS stocks, crypto mining companies as part of his High Conviction Trade Ideas in the US.
He will also be sharing his insights into his high-conviction trade idea in biotech - oncology-focused company, Revolution Medicines. 



The webinar will be hosted on Wednesday, 14 August 2023, 17:00 SGT/HKT.





Register for the Webinar here





Andrei Zakharov is the founder of independent equity research firm Algosun Global Limited, with broad professional experience at leading multinational banks Citibank and Morgan Stanley. Andrei has a respectable background in wealth advisory services for UHNW individuals, alternative energy buy-side research, in-depth analysis of pre-IPO technology unicorns, and portfolio management.


Smartkarma Webinar | High Conviction Trade Ideas in the US

Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

<ul>
<li>Sanofi, a French multinational healthcare company, terminated the SHP2 inhibitor RMC-4630 development and commercialization agreement in 2022. The company did not disclose any specific reasons.</li>
<li>However, Revolution Medicines regained all global rights granted to Sanofi, and management reiterated that RMC-4630 is a potentially important RAS oral inhibitor in the company’s pipeline.</li>
<li>A US-based oncology company completed a public equity offering in March and raised ~$324M of net proceeds. Moreover, Revolution Medicines acquired EQRx and secured access to $1B+ of capital. </li>
</ul>


Sanofi, a French multinational healthcare company, terminated the SHP2 inhibitor RMC-4630 development and commercialization agreement in 2022. The company did not disclose any specific reasons.
However, Revolution Medicines regained all global rights granted to Sanofi, and management reiterated that RMC-4630 is a potentially important RAS oral inhibitor in the company’s pipeline.
A US-based oncology company completed a public equity offering in March and raised ~$324M of net proceeds. Moreover, Revolution Medicines acquired EQRx and secured access to $1B+ of capital. 


2023 High Conviction Update: Revolution Medicines, RVMD/EQRx Deal Adds $1B+ Of Capital

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li><li>Roche Holding Ltd. (RHHBY) reported initial Phase 1 data for oral GLP-1R agonist CT-996 in obesity patients, showing a 6.1% placebo-adjusted weight loss (p&lt;0.001) at four weeks.</li><li>While the weight loss compares favorably with approved injectables at four weeks (1-3% adjusted), the lack of details in the CT996 data, like baseline body weight, limits any cross-trial comparison. </li></ul>

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.Roche Holding Ltd. (RHHBY) reported initial Phase 1 data for oral GLP-1R agonist CT-996 in obesity patients, showing a 6.1% placebo-adjusted weight loss (p&lt;0.001) at four weeks.While the weight loss compares favorably with approved injectables at four weeks (1-3% adjusted), the lack of details in the CT996 data, like baseline body weight, limits any cross-trial comparison. 

United States

Revolution Medicines, Inc. operates as an oncology company. The Company discovers novel targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways. Revolution Medicines serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Revolution Medicines (RVMD US)

Revolution Medicines Inc.: Focus on Novel Combo-Therapeutic Approaches and Broader Genetic Mutations & Other Major Developments - Financial Forecasts

Revolution Medicines has posted the financial and operational updates for the first quarter of 2024, emphasizing significant advancements in its...

Baptista Research

Revolution Medicines Inc.: Initiation Of Coverage - Progression Of Clinical Development Programs & Other Major Drivers

Revolution Medicines reported a decent set of earnings call for the fourth quarter and full year of 2023. Throughout the year, Revolution made...

Baptista Research

Smartkarma Webinar | High Conviction Trade Ideas in the US

Join us as we go live with Smartkarma Insight Provider Andrei Zakharov as he discusses some U.S. SaaS stocks, crypto mining companies, and his high...

Smartkarma Research

2023 High Conviction Update: Revolution Medicines, RVMD/EQRx Deal Adds $1B+ Of Capital

RVMD/EQRx deal will add $1B+ of capital and help to support a rich clinical development pipeline and combination strategies for RAS-addicted cancers.

Andrei Zakharov

Biopharma Week in Review - Jul 22, 2024

Roche Holding Ltd. (RHHBY) reported initial Phase 1 data for oral GLP-1R agonist CT-996 in obesity patients, showing a 6.1% placebo-adjusted weight...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)